CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1342 Lifestyle App Wiki 1.00
drug2117 Ruxolitinib 5 MG Wiki 1.00
drug3012 standard therapy Wiki 0.58
drug601 Colchicine Wiki 0.35

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D001835 Body Weight NIH 0.71
D000073496 Frailty NIH 0.45
D003920 Diabetes Mellitus, NIH 0.32

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000819 Diabetes mellitus HPO 0.32

There is one clinical trial.

Clinical Trials

1 COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial

Patients with mild and severe coronavirus disease 2019 (COVID 19) will be randomized 3:1:1:3 into four groups: colchicine, ruxolitinib, secukinumab, and control groups. Patients will get investigated therapy for 10 days. Patients will be follow-up during 45 days after randomization. Change in clinical assessment score COVID 19 (CAS COVID 19) between baseline and 12th day will be evaluated as the primary endpoint. Risk of death or mechanical ventilation during 45 days after randomization will also be assessed

NCT04403243 COVID 19 Drug: Colchicine Drug: Ruxolitinib 5 MG Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] Other: standard therapy

Primary Outcomes

Description: CAS COVID 19 measures clinical and laboratory parameters in 7 domains: respiratory rate (< 18 - 0 point; 18-22 - 1 point; 23-26 - 2 point; >26 - 3 point) body temperature (35.5 - 37.0 - 0 point; < 35.5 - 1 point; 37.1 - 38.5 - 1 point; > 38.5 - 2 point) Sp02 without support oxygen (> 93% - 0 point; 90-93% - 1 point; < 90% - 2 point) ventilation (not required - 0 point; low-flow ventilation - 1 point; Non-invasive positive pressure ventilation - 2 point; mechanical ventilation - 3 point) C-reactive protein (> 10 - 0 point; 10-59 - 1 point; 60-120 - 2 point; > 120 - 3 point) d - dimer (< 0.51 - 0 point; 0.51 - 2.0 - 1 point; 2.01 - 5.0 - 2, > 5.0 - 3 point) exposure area on lung CT (no pneumonia - 0; 1-24% - 1 point; 25-50% - 2; 51-75% - 3, > 75% - 4). Minimal number of points - 0; max - 20. Lower the score-better health

Measure: change from baseline in clinical assessment score COVID 19 (CAS COVID 19) Frame: baseline

Time: baseline, day 12

Secondary Outcomes

Description: time to death or mechanical ventilation

Measure: Combine endpoint: Time to death or mechanical ventilation

Time: 45 days

Description: Change from baseline in C-reactive protein

Measure: C-reactive protein

Time: baseline, day 12, day 45

Description: Change from baseline in D-dimer

Measure: D-dimer

Time: baseline, day 12, day 45

Description: Change from baseline in EQ-5D-3L™ The EQ-5D-3L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box to the most appropriate statement. This decision results into a 1-digit number, . The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome by patient's own judgement.

Measure: EuroQol Group. EQ-5D™

Time: baseline, day 12, day 45

Description: Change from baseline in exposure area on lung CT

Measure: exposure area on lung CT

Time: baseline, day 12, day 45

No related HPO nodes (Using clinical trials)